HeyJaredVictoria Johnson
- Indexed articles, last 90 days
- 4
- Latest publication
- Oct 1, 2026
- Audience
- Checking…
- Earliest in this view
- Sep 28, 2026
Latest articles
Nail Detachment 4 Times More Common With GLP-1 Use | HCPLive (opens the original)
Read excerpt
Key FactsNail detachment was reported by 39% of GLP-1 receptor agonist users compared with 9% of controls, more than 4 times the rate in a multinational controlled study of 575 users and 1329 controlsAt least 1 nail disorder was reported by 66% of users versus 53% of controls, and nail discoloration affected 46% versus 17%A companion study found unusual hair loss in 50% of users versus 34% of controls, with scalp inflammation accompanying most casesDifferences persisted after adjusting for weigh
Climate Change Tied to Skin Disease Worsening in 42% of Countries | HCPLive (opens the original)
Read excerpt
Key FactsMore than 40% of countries worldwide (42.6% of 136 surveyed) reported climate-related changes in skin disease prevalence or severity, per the SkinObservatory study presented at EADV Congress 2026Low-income (55.6%) and lower-middle-income (52.5%) countries reported changes far more often than high-income countries (28.3%)Among countries reporting climate-associated effects, heat rashes (81.0%) and inflammatory skin disease (75.9%) were the most commonly reported changes42.9% of responden
FDA Accepts Resubmitted BLA for RelabotulinumtoxinA for Glabellar and Lateral Canthal Lines | HCPLive (opens the original)
Read excerpt
Drug name and class: RelabotulinumtoxinA; botulinum toxin type A neuromodulatorNews: BLA accepted for temporary improvement of moderate-to-severe glabellar and lateral canthal lines in adultsTrial program: READY phase III clinical program (READY-1 through READY-4; >1,900 participants)Key efficacy outcomes: Key safety signals: Low incidence of mild TEAEs; no unexpected safety signals in published data¹
FDA Updates Sotatercept Label with HYPERION Data in Early PAH | HCPLive (opens the original)
Read excerpt
Sotatercept-csrk (WINREVAIR) is FDA-approved for adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity and functional class and reduce the risk of clinical worsening events, including hospitalization, lung transplantation, and death. Sotatercept is an activin signaling inhibitor that rebalances pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in pulmonary arterial hypertension. Adding sotatercept to background therapy in adult
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.